Developer docs
API playgroundTry for free, no card

Search company profiles

Novelty Nobility

Full company profile

uuid0000zea

Namestring
Novelty Nobility
Legal namestring
NOVELTY NOBILITY Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Novelty Nobility Inc. is a clinical-stage South Korean biotechnology company founded in September 2017 and headquartered in Seongnam-si, Gyeonggi-do (Pangyo), with a research institute also located in Seongnam's Sujeong-gu area near Ajou University. The company focuses on discovering and developing antibody-based therapeutics against novel angiogenesis targets, with primary emphasis on the SCF/c-KIT signaling pathway — a mechanism the founding team first identified in 2012 as a VEGF-independent driver of angiogenesis and vascular permeability, offering a potential answer to the up to 40% of patients refractory to anti-VEGF therapy. Its therapeutic focus spans ophthalmology (wet AMD, diabetic macular edema, geographic atrophy) and oncology (small cell lung carcinoma, GIST, leukemia, glioblastoma, ovarian cancer, and via NN3206, Ras-mutant pancreatic cancer), with mast cell-driven autoimmune disease (chronic urticaria) addressed through its licensed NN2802 program.

The company's technology stack rests on two proprietary platforms. PREXISE-D is a fit-for-purpose antibody design and discovery engine using a Humice-based discovery system, while PREXISE-L is a patent-protected linker technology employing an Fc-III peptide (FcBP) with p-benzoylphenylalanine (pBpa) for photoaffinity cross-linking to Met252 of IgG antibodies, enabling site-specific payload conjugation and stable drug-to-antibody ratio (DAR) control for antibody-drug conjugates. The pipeline comprises four disclosed candidates: NN4101, a first-in-class bispecific antibody combining anti-c-Kit with a VEGF trap for neovascular retinal disease; NN2101, an anti-c-KIT monoclonal antibody for retinal disease preparing IND submission; NN3201, an anti-c-Kit ADC for c-KIT-positive tumors; and NN3206, a CDCP1-targeting ADC for pancreatic cancer. NN2802 (VB517), a fully human anti-c-KIT mAb for mast cell-driven autoimmune diseases, has been licensed exclusively to ValenzaBio.

Novelty Nobility operates a B2B licensing and partnership business model. Revenue is generated through upfront payments, development and commercialization milestones, and royalties from licensing drug candidates to larger pharmaceutical partners, rather than through direct product sales. The company has raised approximately USD 58.8 million cumulatively across equity rounds — Series B of 34.1 billion KRW in May 2022 at approximately 79 billion KRW valuation, and Series C of 23.3 billion KRW in November 2024 at approximately 1,200 billion KRW post-money valuation — supplemented by a USD 7 million upfront payment from the February 2022 ValenzaBio licensing agreement, which carries a headline value of up to USD 733.25 million in milestones plus royalties. Distribution is exclusively through enterprise licensing arrangements, with manufacturing and process development supported by AGC Biologics in Denmark and Japan. The company is pursuing a KOSDAQ IPO after a previous filing was voluntarily withdrawn in June 2025, with a lead manager contract signed with Hana Securities in April 2026.

Short descriptiontext

Novelty Nobility is a clinical-stage South Korean biotech developing antibody-based therapeutics targeting the SCF/c-KIT pathway for ophthalmology and oncology indications. The company licenses drug candidates to pharmaceutical partners using its proprietary PREXISE-D antibody discovery and PREXISE-L ADC linker platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, antibody-drug conjugates, bispecific antibodies, oncology drug development, ophthalmic therapeutics
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals (Antibody Therapeutics)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

Novelty Nobility generates revenue through licensing out its drug candidates to pharmaceutical partners. The company receives upfront payments, milestone payments tied to clinical development and commercialization, and royalties on net sales.

noveltynobility.com
2Series Funding
TypeOne Time License
Description

The company raises capital through equity financing rounds. Series B raised 34.1 billion won in 2022 with ~79 billion won valuation. Series C raised 23.3 billion won in 2024.

thebell.co.kr
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1PREXISE-D
Description

Fit-for-purpose antibody design and discovery platform technology

noveltynobility.com
+1 more record
Core offering1 text field

Novelty Nobility is a clinical-stage biotech that discovers and develops antibody-based therapeutics — monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) — targeting the SCF/c-KIT pathway for oncology (c-KIT-positive tumors such as SCLC, GIST, leukemia) and ophthalmology (neovascular retinal diseases including wet AMD and diabetic macular edema). The company monetizes its pipeline through exclusive worldwide licensing and co-development deals with larger pharmaceutical partners, while advancing internal candidates through preclinical and IND-enabling stages.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Up to 40% of patients are refractory to anti-VEGF treatment
Product overview1 text field

Novelty Nobility is a clinical-stage biotech company developing monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) targeting primarily oncology and ophthalmology indications. The company's technology platform consists of PREXISE-D (antibody discovery) and PREXISE-L (ADC linker technology). The pipeline includes NN4101 (bispecific antibody for retinal diseases), NN3201 (ADC for c-Kit positive tumors), NN3206 (CDCP1-targeting ADC), and NN2802 (licensed to ValenzaBio for autoimmune diseases).

Product and service7 records
1PREXISE-D
CategoryAntibody Discovery Platform
Description

Fit-for-purpose antibody design and discovery platform using a Humice-based antibody discovery engine. Used internally by Novelty Nobility to identify and optimize novel therapeutic antibodies against specific targets such as c-KIT and CDCP1.

2PREXISE-L
CategoryADC Linker Technology
Description

Patent-protected proprietary linker platform technology that enables site-specific conjugation of various payloads to an intact antibody. PREXISE-L uses an Fc-III peptide (FcBP) incorporating p-benzoylphenylalanine (pBpa) for photoaffinity cross-linking reaction with Met252 of IgG antibody, resulting in stable control of drug-to-antibody ratio (DAR) for antibody-drug conjugate development.

3NN4101
CategoryBispecific Antibody (Ophthalmology)
Description

First-in-class bispecific antibody combining an anti-c-Kit monoclonal antibody fused with a VEGF trap for the treatment of neovascular retinal diseases. Cell line development completed at AGC Biologics' Copenhagen facility with technology transfer to Chiba, Japan for next-phase GMP manufacturing.

4NN2101
CategoryMonoclonal Antibody (Ophthalmology)
Description

Monoclonal antibody targeting the c-KIT receptor for retinal disease treatment. Being prepared for IND application submission to the U.S. FDA.

5NN3201
CategoryAntibody-Drug Conjugate (Oncology)
Description

Anti-c-Kit antibody-drug conjugate (ADC) for treatment of c-Kit-positive tumors including small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST).

6NN3206
CategoryAntibody-Drug Conjugate (Oncology)
Description

CDCP1-targeting antibody-drug conjugate demonstrating efficacy in Ras-mutant pancreatic cancer models, outperforming standard therapies.

7NN2802 (VB517)
CategoryMonoclonal Antibody (Autoimmune)
Description

Fully human anti-c-Kit monoclonal antibody for mast cell-driven autoimmune diseases. Licensed exclusively worldwide to ValenzaBio in February 2022 for development of chronic urticaria and other autoimmune indications, with $7 million upfront and up to $733.25 million in development and commercialization milestones plus royalties on net sales.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-04
Description

Novelty Nobility expanded its manufacturing partnership with AGC Biologics for process development and GMP production of its bispecific antibody candidate NN4101. Cell line development was completed at AGC Biologics' Copenhagen facility, with technology transfer to Chiba, Japan location for next-phase manufacturing. NN4101 is a first-in-class anti-c-Kit monoclonal antibody fused with a VEGF trap for neovascular retinal diseases.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-10-28
Description

Novelty Nobility entered into a joint research and development agreement with GC Biopharma for geographic atrophy therapies. This partnership leverages Novelty Nobility's antibody technology with GC Biopharma's manufacturing and development capabilities.

3ValenzaBio
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-02-15
Description

Novelty Nobility granted exclusive worldwide license to ValenzaBio for VB517 (NN2802), a potentially best-in-class anti-c-KIT monoclonal antibody for mast cell-driven autoimmune diseases. Deal terms included $7 million upfront payment and up to $733.25 million in milestones plus royalties. ValenzaBio assumed all development and commercialization costs.

noveltynobility.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC developer with multiple pipeline candidates in oncology. Direct peer to Novelty Nobility in ADC technology and business model, with overlapping focus on novel targets for cancer treatment.

TypeDirect peer
Description

Korean clinical-stage biotech developing antibody-drug conjugates using proprietary linker and conjugation technologies. Direct peer to Novelty Nobility in ADC platform technology and geographic market, both focused on oncology applications of ADC technology.

TypeDirect peer
Description

Clinical-stage antibody biotech with computational discovery platform for developing antibody therapeutics against difficult targets. Similar size and stage as Novelty Nobility, with comparable business model of developing innovative antibody candidates.

TypeBroad incumbent
Description

Danish biotechnology company that pioneered bispecific antibody technology (DuoBody platform) and developed multiple approved antibodies. Broader incumbent in the antibody space with overlapping bispecific antibody focus relevant to Novelty Nobility's NN4101 program.

TypeDirect peer
Description

Clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen) and multiple pipeline candidates. Direct peer to Novelty Nobility in ADC technology and clinical stage, with similar focus on novel linkers and payloads.

TypeDirect peer
Description

Korean clinical-stage biotech developing bispecific antibodies using proprietary Grabody platform. Direct peer to Novelty Nobility in bispecific antibody technology and Korean market, with similar focus on oncology and immunology.

TypeDirect peer
Description

Clinical-stage biotech with proprietary DART platform for bispecific antibodies. Direct peer to Novelty Nobility in bispecific antibody technology, with similar focus on oncology applications and clinical-stage development.

TypeBroad incumbent
Description

Korean pharmaceutical company with established biologics pipeline including antibody therapeutics. Broader incumbent with relevant biologics manufacturing and development capabilities, and a known licensing partner for many Korean biotechs.

TypeEmerging player
Description

Canadian antibody discovery platform company with AI-enabled technology. Comparable in antibody discovery and engineering approach, though larger and at later stage than Novelty Nobility. Relevant as a platform peer for the PREXISE-D technology.

TypeRegional player
Description

Korean clinical-stage biotech developing antibody and protein therapeutics. Regional peer to Novelty Nobility in Korean biotech market, with similar clinical stage and antibody focus, though different therapeutic targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novelty Nobility

Biopharmaceuticals (Antibody Therapeutics)noveltynobility.com

Novelty Nobility is a clinical-stage South Korean biotech developing antibody-based therapeutics targeting the SCF/c-KIT pathway for ophthalmology and oncology indications. The company licenses drug candidates to pharmaceutical partners using its proprietary PREXISE-D antibody discovery and PREXISE-L ADC linker platforms.

What Novelty Nobility does

Novelty Nobility Inc. is a clinical-stage South Korean biotechnology company founded in September 2017 and headquartered in Seongnam-si, Gyeonggi-do (Pangyo), with a research institute also located in Seongnam's Sujeong-gu area near Ajou University. The company focuses on discovering and developing antibody-based therapeutics against novel angiogenesis targets, with primary emphasis on the SCF/c-KIT signaling pathway — a mechanism the founding team first identified in 2012 as a VEGF-independent driver of angiogenesis and vascular permeability, offering a potential answer to the up to 40% of patients refractory to anti-VEGF therapy. Its therapeutic focus spans ophthalmology (wet AMD, diabetic macular edema, geographic atrophy) and oncology (small cell lung carcinoma, GIST, leukemia, glioblastoma, ovarian cancer, and via NN3206, Ras-mutant pancreatic cancer), with mast cell-driven autoimmune disease (chronic urticaria) addressed through its licensed NN2802 program.

The company's technology stack rests on two proprietary platforms. PREXISE-D is a fit-for-purpose antibody design and discovery engine using a Humice-based discovery system, while PREXISE-L is a patent-protected linker technology employing an Fc-III peptide (FcBP) with p-benzoylphenylalanine (pBpa) for photoaffinity cross-linking to Met252 of IgG antibodies, enabling site-specific payload conjugation and stable drug-to-antibody ratio (DAR) control for antibody-drug conjugates. The pipeline comprises four disclosed candidates: NN4101, a first-in-class bispecific antibody combining anti-c-Kit with a VEGF trap for neovascular retinal disease; NN2101, an anti-c-KIT monoclonal antibody for retinal disease preparing IND submission; NN3201, an anti-c-Kit ADC for c-KIT-positive tumors; and NN3206, a CDCP1-targeting ADC for pancreatic cancer. NN2802 (VB517), a fully human anti-c-KIT mAb for mast cell-driven autoimmune diseases, has been licensed exclusively to ValenzaBio.

Novelty Nobility operates a B2B licensing and partnership business model. Revenue is generated through upfront payments, development and commercialization milestones, and royalties from licensing drug candidates to larger pharmaceutical partners, rather than through direct product sales. The company has raised approximately USD 58.8 million cumulatively across equity rounds — Series B of 34.1 billion KRW in May 2022 at approximately 79 billion KRW valuation, and Series C of 23.3 billion KRW in November 2024 at approximately 1,200 billion KRW post-money valuation — supplemented by a USD 7 million upfront payment from the February 2022 ValenzaBio licensing agreement, which carries a headline value of up to USD 733.25 million in milestones plus royalties. Distribution is exclusively through enterprise licensing arrangements, with manufacturing and process development supported by AGC Biologics in Denmark and Japan. The company is pursuing a KOSDAQ IPO after a previous filing was voluntarily withdrawn in June 2025, with a lead manager contract signed with Hana Securities in April 2026.

Novelty Nobility firmographics

Firmographics
Name
Novelty Nobility
Legal name
NOVELTY NOBILITY Inc.
Website
https://noveltynobility.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Novelty Nobility is a clinical-stage South Korean biotech developing antibody-based therapeutics targeting the SCF/c-KIT pathway for ophthalmology and oncology indications. The company licenses drug candidates to pharmaceutical partners using its proprietary PREXISE-D antibody discovery and PREXISE-L ADC linker platforms.
Ownership category
akta.pro rank

Novelty Nobility industry classification

Industry
Product category
Biopharmaceuticals (Antibody Therapeutics)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody therapeutics
  • Antibody-drug conjugates
  • Bispecific antibodies
  • Oncology drug development
  • Ophthalmic therapeutics

Where Novelty Nobility is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Novelty Nobility business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing Revenue: Novelty Nobility generates revenue through licensing out its drug candidates to pharmaceutical partners. The company receives upfront payments, milestone payments tied to clinical development and commercialization, and royalties on net sales.
  2. Series Funding: The company raises capital through equity financing rounds. Series B raised 34.1 billion won in 2022 with ~79 billion won valuation. Series C raised 23.3 billion won in 2024.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Novelty Nobility product offering

Product offering

Core offering

Novelty Nobility is a clinical-stage biotech that discovers and develops antibody-based therapeutics — monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) — targeting the SCF/c-KIT pathway for oncology (c-KIT-positive tumors such as SCLC, GIST, leukemia) and ophthalmology (neovascular retinal diseases including wet AMD and diabetic macular edema). The company monetizes its pipeline through exclusive worldwide licensing and co-development deals with larger pharmaceutical partners, while advancing internal candidates through preclinical and IND-enabling stages.

Product overview

Novelty Nobility is a clinical-stage biotech company developing monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) targeting primarily oncology and ophthalmology indications. The company's technology platform consists of PREXISE-D (antibody discovery) and PREXISE-L (ADC linker technology). The pipeline includes NN4101 (bispecific antibody for retinal diseases), NN3201 (ADC for c-Kit positive tumors), NN3206 (CDCP1-targeting ADC), and NN2802 (licensed to ValenzaBio for autoimmune diseases).

Differentiator

Problem solved

Functional benefit

Brands

  • PREXISE-D: Fit-for-purpose antibody design and discovery platform technology
  • PREXISE-L

Products and services

  • PREXISE-D Fit-for-purpose antibody design and discovery platform using a Humice-based antibody discovery engine. Used internally by Novelty Nobility to identify and optimize novel therapeutic antibodies against specific targets such as c-KIT and CDCP1.
  • PREXISE-L Patent-protected proprietary linker platform technology that enables site-specific conjugation of various payloads to an intact antibody. PREXISE-L uses an Fc-III peptide (FcBP) incorporating p-benzoylphenylalanine (pBpa) for photoaffinity cross-linking reaction with Met252 of IgG antibody, resulting in stable control of drug-to-antibody ratio (DAR) for antibody-drug conjugate development.
  • NN4101 First-in-class bispecific antibody combining an anti-c-Kit monoclonal antibody fused with a VEGF trap for the treatment of neovascular retinal diseases. Cell line development completed at AGC Biologics' Copenhagen facility with technology transfer to Chiba, Japan for next-phase GMP manufacturing.
  • NN2101 Monoclonal antibody targeting the c-KIT receptor for retinal disease treatment. Being prepared for IND application submission to the U.S. FDA.
  • NN3201 Anti-c-Kit antibody-drug conjugate (ADC) for treatment of c-Kit-positive tumors including small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST).
  • NN3206 CDCP1-targeting antibody-drug conjugate demonstrating efficacy in Ras-mutant pancreatic cancer models, outperforming standard therapies.
  • NN2802 (VB517) Fully human anti-c-Kit monoclonal antibody for mast cell-driven autoimmune diseases. Licensed exclusively worldwide to ValenzaBio in February 2022 for development of chronic urticaria and other autoimmune indications, with $7 million upfront and up to $733.25 million in development and commercialization milestones plus royalties on net sales.

Quantifiable outcome

  • Up to 40% of patients are refractory to anti-VEGF treatment

Companies that use Novelty Nobility

Customer profile

Segments3 records

Ideal customer profiles2 records

Novelty Nobility technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Novelty Nobility partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • AGC BiologicscoreTechnology or Integration · 4 May 2026Novelty Nobility expanded its manufacturing partnership with AGC Biologics for process development and GMP production of its bispecific antibody candidate NN4101. Cell line development was completed at AGC Biologics' Copenhagen facility, with technology transfer to Chiba, Japan location for next-phase manufacturing. NN4101 is a first-in-class anti-c-Kit monoclonal antibody fused with a VEGF trap for neovascular retinal diseases.
  • GC BiopharmamajorStrategic or Co-development Partner · 28 October 2024Novelty Nobility entered into a joint research and development agreement with GC Biopharma for geographic atrophy therapies. This partnership leverages Novelty Nobility's antibody technology with GC Biopharma's manufacturing and development capabilities.
  • ValenzaBiocoreOEM/ Whitelabel/ Licensing Partner · 15 February 2022Novelty Nobility granted exclusive worldwide license to ValenzaBio for VB517 (NN2802), a potentially best-in-class anti-c-KIT monoclonal antibody for mast cell-driven autoimmune diseases. Deal terms included $7 million upfront payment and up to $733.25 million in milestones plus royalties. ValenzaBio assumed all development and commercialization costs.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Novelty Nobility competitors and assessment

Company assessment

Direct peers

  • Pyxis Oncology: Clinical-stage ADC developer with multiple pipeline candidates in oncology. Direct peer to Novelty Nobility in ADC technology and business model, with overlapping focus on novel targets for cancer treatment.
  • LegoChem Biosciences: Korean clinical-stage biotech developing antibody-drug conjugates using proprietary linker and conjugation technologies. Direct peer to Novelty Nobility in ADC platform technology and geographic market, both focused on oncology applications of ADC technology.
  • Adagene: Clinical-stage antibody biotech with computational discovery platform for developing antibody therapeutics against difficult targets. Similar size and stage as Novelty Nobility, with comparable business model of developing innovative antibody candidates.
  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen) and multiple pipeline candidates. Direct peer to Novelty Nobility in ADC technology and clinical stage, with similar focus on novel linkers and payloads.
  • ABL Bio: Korean clinical-stage biotech developing bispecific antibodies using proprietary Grabody platform. Direct peer to Novelty Nobility in bispecific antibody technology and Korean market, with similar focus on oncology and immunology.
  • MacroGenics: Clinical-stage biotech with proprietary DART platform for bispecific antibodies. Direct peer to Novelty Nobility in bispecific antibody technology, with similar focus on oncology applications and clinical-stage development.

Broad incumbents

  • Genmab: Danish biotechnology company that pioneered bispecific antibody technology (DuoBody platform) and developed multiple approved antibodies. Broader incumbent in the antibody space with overlapping bispecific antibody focus relevant to Novelty Nobility's NN4101 program.
  • Hanmi Pharmaceutical: Korean pharmaceutical company with established biologics pipeline including antibody therapeutics. Broader incumbent with relevant biologics manufacturing and development capabilities, and a known licensing partner for many Korean biotechs.

Emerging players

  • AbCellera Biologics: Canadian antibody discovery platform company with AI-enabled technology. Comparable in antibody discovery and engineering approach, though larger and at later stage than Novelty Nobility. Relevant as a platform peer for the PREXISE-D technology.

Regional players

  • Genexine: Korean clinical-stage biotech developing antibody and protein therapeutics. Regional peer to Novelty Nobility in Korean biotech market, with similar clinical stage and antibody focus, though different therapeutic targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Novelty Nobility social profiles

Digital presence

Novelty Nobility financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novelty Nobility leadership team

Management profile

Number of profiles

Profiles6 records

Novelty Nobility funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novelty Nobility M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novelty Nobility

What does Novelty Nobility do?

Novelty Nobility is a clinical-stage biotech that discovers and develops antibody-based therapeutics — monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) — targeting the SCF/c-KIT pathway for oncology (c-KIT-positive tumors such as SCLC, GIST, leukemia) and ophthalmology (neovascular retinal diseases including wet AMD and diabetic macular edema). The company monetizes its pipeline through exclusive worldwide licensing and co-development deals with larger pharmaceutical partners, while advancing internal candidates through preclinical and IND-enabling stages.

Is Novelty Nobility a public or private company?

Novelty Nobility is a private company. It is classified as venture growth investor backed and is currently operating.

When was Novelty Nobility founded?

Novelty Nobility was founded in 2017. It employs 1 to 10 people.

Where is Novelty Nobility based?

Novelty Nobility is headquartered in Seongnam, South Korea, in the Asia region.

How does Novelty Nobility make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are series Funding.

Who are Novelty Nobility's main competitors?

Direct peers on record are Pyxis Oncology, LegoChem Biosciences, Adagene, Mersana Therapeutics, ABL Bio and MacroGenics. Broad incumbents are Genmab and Hanmi Pharmaceutical. AbCellera Biologics is listed as an emerging player. Genexine is listed as a regional player.

Does Novelty Nobility have an API?

No public API is recorded for Novelty Nobility.

What industry is Novelty Nobility in?

Novelty Nobility's product category is Biopharmaceuticals (Antibody Therapeutics). Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsNovelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP ManufacturingNovelty Nobility expanded its agreement with CDMO AGC Biologics to advance its bispecific antibody NN4101 through process development and GMP manufacturing at AGC's Chiba facility. The project follows cell line development in Copenhagen and will use AGC's single-use bioreactor technology. AGC is also expanding its Yokohama facility to support growing demand.BioSpaceNovelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug CandidateNovelty Nobility expanded its manufacturing agreement with AGC Biologics to advance its bispecific antibody NN4101 for neovascular retinal diseases. The partnership continues from the previous year, with cell line development completed in Copenhagen and now on track for GMP manufacturing in Chiba, Japan. AGC Biologics is also expanding with a new Yokohama facility to meet growing demand.GlobeNewswireNovelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug CandidateNovelty Nobility expanded its manufacturing agreement with AGC Biologics to advance its bispecific antibody candidate NN4101 through process development and GMP manufacturing at AGC's Chiba facility. The project, which completed cell line development in Copenhagen, is on track for tech transfer to Chiba. AGC is also expanding with a new Yokohama facility to meet growing demand.GlobeNewswireNovelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug CandidateNovelty Nobility, a clinical-stage biotech company based in South Korea, has expanded its manufacturing agreement with AGC Biologics to advance its bispecific antibody drug candidate NN4101 through process development and GMP manufacturing at AGC Biologics' facility in Chiba, Japan. The bispecific antibody, which uniquely combines an anti-c-Kit monoclonal antibody with a VEGF trap, is a first-in-class candidate intended for treating neovascular retinal diseases, with cell line development previously completed in Copenhagen, Denmark. AGC Biologics is also expanding its Japan presence with a new Yokohama facility featuring single-use bioreactor technology to meet growing demand for biopharmaceutical manufacturing.GlobeNewswire노벨티 노빌리티 (Novelty Nobility), 이중특이성 항체 개발 위해 AGC Biologics와 협력 확대Korean clinical-stage biotech company Novelty Nobility has expanded its manufacturing contract with AGC Biologics for process development and GMP production of its bispecific antibody candidate NN4101, marking their second collaboration following initial work initiated last year. Cell line development was successfully completed at AGC Biologics' Copenhagen facility, with technology transfer now underway to its Chiba, Japan location for the next critical manufacturing phase. The first-in-class bispecific antibody targets neovascular retinal diseases by combining an anti-c-Kit monoclonal antibody with a VEGF trap, offering a differentiated therapeutic option for patients.GlobeNewswireノベルティ・ノビリティ、AGCバイオロジクスと提携し、二重特異性抗体候補薬の開発を推進Korea-based clinical-stage biotech company Novelty Nobility has expanded its manufacturing partnership with AGC Biologics, a global CDMO, to advance its bispecific antibody candidate NN4101 through process development and GMP manufacturing at AGC Biologics' Chiba facility in Japan. This second partnership builds on successful cell line development completed in Copenhagen, Denmark, and the candidate — a first-in-class anti-c-Kit monoclonal antibody fused with a VEGF trap — is being developed for the treatment of neovascular retinal diseases. AGC Biologics is simultaneously expanding its Japanese operations with a new Yokohama facility to meet growing regional and global demand for biopharmaceutical manufacturing.NewstofNobility receiving 50 billion investment, will it gain momentum for relisting - News TopCoas will invest 50 billion won in Novelty Nobility, with 15 billion won in new shares and 20 billion won in convertible bonds. The funds will support a Phase 2a clinical trial for NN2802 by mid-next year, with potential relisting and technology transfer depending on results.E-ScienceCoas, with the acquisition of 'Novelty Nobility', is making a full-scale entry into the bio business - Economy ScienceCoas announced a 50 billion won investment in antibody drug developer Novelty Nobility, making it a subsidiary. Novelty Nobility has antibody pipelines including NN2802 for allergies, preparing for Phase 1b/2a trials. The company plans large-scale technology exports in 2026.MkKOAS acquires Novelty Nobility to enter biopharma sectorKOAS acquired a 14.3% stake in antibody developer Novelty Nobility for about 15 billion won on Sept. 8, making it its largest shareholder. The deal includes a total investment of 50 billion won, and Novelty's pipeline includes NN2802 in Phase 1b/2a and NN4101 for retinal disease. KOAS targets global licensing-out in 2026.IkoasCoasCoas acquired antibody-based biotech Novelty Nobility, investing 50 billion won to become a major shareholder. The deal marks Coas's entry into the pharmaceutical industry, with Novelty Nobility's antibody pipelines including NN3201, NN3206, and NN2802. Coas aims to grow into a global big pharma.